The U.S. Food and Drug Administration (FDA) has issued an untitled letter to Pinnacle Biologics, stating that promotional videos for its cancer therapy Photofrin presented misleading information about the drug’s approved uses. The agency concluded that the materials failed to adequately communicate the treatment’s specific indications and limitations, potentially leaving healthcare professionals with an inaccurate understanding of the therapy’s approved applications.
Summary
- The FDA issued an untitled letter to Pinnacle Biologics regarding promotional videos for Photofrin.
- The agency said the videos created a misleading impression of the drug’s approved indications.
- According to the FDA, important information about eligible patient populations and treatment limitations was omitted or inadequately presented.
- The videos were intended for healthcare professionals and explained Photofrin’s mechanism of action.
- The FDA has requested that Pinnacle cease using the materials and respond with a corrective action plan.
The regulatory action follows the FDA’s review of two promotional videos submitted by Pinnacle Biologics featuring Photofrin, a photodynamic therapy used to treat certain cancers. The materials, identified as the “Esophageal Cancer_MOA Video” and the “NSCLC_MOA Video,” were designed to explain the drug’s mechanism of action to healthcare professionals. However, FDA reviewers concluded that the presentations overstated the scope of the drug’s approved uses by failing to clearly describe the patient populations for whom the therapy is indicated.
Photofrin is a light-activated therapy used in photodynamic treatment. Patients first receive an intravenous injection of the drug, and approximately 40 to 50 hours later clinicians expose the targeted tissue to a red laser light. The light activates the drug, producing reactive oxygen molecules that destroy nearby cancer cells while limiting damage to surrounding healthy tissue. The therapy has been approved for specific oncology indications for many years and remains one of the best-known photodynamic cancer treatments.
According to the FDA, the videos introduced Photofrin as a treatment for esophageal cancer, high-grade dysplasia associated with Barrett’s esophagus, and non-small cell lung cancer. While those disease names appeared prominently, the agency said the presentations omitted important qualifying language that defines which patients are eligible for treatment under the drug’s FDA-approved prescribing information. As a result, viewers could reasonably conclude that the therapy is approved for broader use than is actually the case.
The agency acknowledged that the complete indications eventually appeared later in the videos during the safety section. However, FDA reviewers determined that this did not sufficiently correct the misleading impression created at the beginning of the presentations. The agency noted that the approved indications were displayed only briefly in a small, plain font while viewers were simultaneously expected to absorb extensive risk information, making it difficult for healthcare professionals to adequately process and understand the information.
The FDA also emphasized that promotional materials must present benefit and risk information in a truthful, balanced, and non-misleading manner. Promotional content aimed at healthcare professionals is expected to accurately reflect a product’s approved labeling, including any restrictions on patient populations or intended uses. When materials omit key limitations or minimize qualifying information, the agency may determine that they create a misleading impression even if the omitted information appears elsewhere in the presentation.
The untitled letter does not allege problems with the safety or effectiveness of Photofrin itself. Instead, it focuses solely on how the product was promoted. Unlike an FDA warning letter, an untitled letter generally addresses violations that the agency believes should be corrected but do not meet the threshold for more severe enforcement action. Companies receiving such letters are typically expected to discontinue the cited promotional materials, assess whether similar materials contain comparable issues, and outline corrective actions to the agency.
The FDA has requested that Pinnacle Biologics submit a written response describing the steps it will take to address the concerns, including whether it intends to discontinue the videos and develop corrective communications if necessary. The agency also asked the company to identify any other promotional materials that contain similar claims and explain how those materials will be brought into compliance.
The case highlights the FDA’s continued oversight of pharmaceutical marketing, particularly promotional materials directed at healthcare professionals. The agency routinely reviews advertisements, websites, videos, and educational content to ensure they accurately reflect approved prescribing information and do not overstate a drug’s benefits or broaden its labeled indications. Promotional compliance remains a key area of regulatory enforcement across the pharmaceutical industry.
Photofrin Promotional Materials Receive FDA Attention
Photofrin, a light-activated cancer therapy marketed by Pinnacle Biologics, has become the subject of an FDA citation concerning promotional videos used to communicate information about the treatment. The regulatory action underscores the importance of ensuring that promotional materials for Photofrin accurately present both the benefits and potential risks associated with prescription medicines.
The FDA routinely monitors pharmaceutical advertising and promotional content to help ensure healthcare professionals and patients receive balanced, evidence-based information. The agency’s review of Photofrin promotional materials reflects its ongoing oversight of drug marketing practices.
Photofrin Marketing Practices Under Regulatory Review
According to the FDA, certain promotional videos related to Photofrin raised concerns regarding compliance with federal regulations governing prescription drug promotion. Regulatory agencies require that promotional communications provide a fair balance between a product’s benefits and its risks while avoiding statements that could be misleading.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
